Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-30 and CHOP in Newly Diagnosed ALCL
NCT00365274Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iratumumab in anaplastic large cell lymphoma (ALCL), sponsored by National Cancer Institute. Started Aug 2006; status: terminated.
02
Drugs
iratumumab
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00365274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365274.